

JURISDICTION AND VENUE

5. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331 and 1338(a).

6. This Court has personal jurisdiction over Teva because, *inter alia*, Teva is a Delaware corporation and because of its continuous and systematic contacts within this judicial district.

7. Venue is proper in this judicial district pursuant to 28 U.S.C. §§ 1391(c) and 1400(b).

FACTUAL BACKGROUND

8. On May 8, 2001, the '398 patent, entitled "Multiparticulate Modified Release Composition," was duly and legally issued to Elan Corporation, plc ("Elan") as assignee. Elan's rights were subsequently transferred to Alkermes. A true and correct copy of the '398 patent is attached as Exhibit A.

9. On May 4, 2004, the '325 patent, entitled "Multiparticulate Modified Release Composition," was duly and legally issued to Elan as assignee. Elan's rights were subsequently transferred to Alkermes. A true and correct copy of the '325 patent is attached as Exhibit B.

10. On May 26, 2005, the United States Food And Drug Administration ("FDA") approved new drug application No. 21-802 for FOCALIN® XR capsules, which contain dexamethylphenidate hydrochloride, under § 505(a) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 355(a), for the treatment of Attention Deficit Hyperactivity Disorder. The '398 and '325 patents are listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* (the "Orange Book") for FOCALIN® XR capsules.

11. On information and belief, Teva submitted to the FDA abbreviated new drug application (“ANDA”) No. 202731 under § 505(j) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 355(j), seeking approval to engage in the commercial manufacture, use, and sale of dexmethylphenidate hydrochloride extended-release capsules in the 25, 30, 35, and 40 mg strengths, as generic versions of the FOCALIN® XR 25, 30, 35, and 40 mg capsules.

12. By letters dated March 11, 2011, and October 19, 2011 (the “Teva Letters”), Teva advised Elan that it had submitted ANDA No. 202731 seeking approval to manufacture, use, or sell generic dexmethylphenidate hydrochloride extended-release capsules in the 25, 30, 35, and 40 mg strengths prior to the expiration of the ’398 and ’325 patents.

13. Elan previously litigated the ’398 and ’325 patents against Teva with respect to Teva’s ANDA seeking approval to manufacture, use, or sell generic dexmethylphenidate hydrochloride extended-release capsules in the 5, 10, 15, and 20 mg strengths. That litigation was settled pursuant to a settlement agreement.

14. Alkermes and Teva are currently litigating the ’398 and ’325 patents with respect to ANDA No. 202731 seeking approval to manufacture, use, or sell generic dexmethylphenidate hydrochloride extended-release capsules in the 30 mg and 40 mg strengths. The complaint in that action was filed on April 25, 2011. *See Alkermes Pharma Ireland Ltd. v. Teva Pharm. USA, Inc.*, C.A. No. 11-367-SLR (D. Del.). Teva has moved to dismiss that action.

15. The Teva Letters also advised Elan that Teva’s ANDA included a certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) that, in Teva’s opinion, the manufacture, use, or sale of the proposed generic dexmethylphenidate hydrochloride extended-release capsules described in Teva’s ANDA will not infringe any claim of the ’398 and ’325 patents, and that those claims are invalid.

COUNT I

16. Alkermes incorporates each of the preceding paragraphs 1 to 15 as if fully set forth herein.

17. Teva's submission of ANDA No. 202731 to the FDA for dexmethylphenidate hydrochloride extended-release capsules in the 25, 30, 35, and 40 mg strengths, including the § 505(j)(2)(A)(vii)(IV) allegations, constitutes infringement of the '398 patent under 35 U.S.C. § 271(e)(2)(A). Teva's commercial manufacture, offer for sale, or sale of the proposed generic for dexmethylphenidate hydrochloride extended-release capsules in the 25, 30, 35, and 40 mg strengths would infringe the '398 patent.

18. On information and belief, Teva was aware of the existence of the '398 patent and was aware that the filing of ANDA No. 202731 and certification with respect to the '398 patent constituted infringement of that patent. This is an exceptional case.

COUNT II

19. Alkermes incorporates each of the preceding paragraphs 1 to 18 as if fully set forth herein.

20. Teva's submission of ANDA No. 202731 to the FDA for dexmethylphenidate hydrochloride extended-release capsules in the 25, 30, 35, and 40 mg strengths, including the § 505(j)(2)(A)(vii)(IV) allegations, constitutes infringement of the '325 patent under 35 U.S.C. § 271(e)(2)(A). Teva's commercial manufacture, offer for sale, or sale of the proposed generic for dexmethylphenidate hydrochloride extended-release capsules in the 25, 30, 35, and 40 mg strengths would infringe the '325 patent.

21. On information and belief, Teva was aware of the existence of the '325 patent and was aware that the filing of ANDA No. 202731 and certification with respect to the '325 patent constituted infringement of that patent. This is an exceptional case.

PRAYER FOR RELIEF

WHEREFORE, Alkermes respectfully requests the following relief:

- A. A judgment that Teva has infringed the '398 and '325 patents;
- B. An order, pursuant to 35 U.S.C. § 271(e)(4)(A), that the effective date of any approval of ANDA No. 202731 for dexamethylphenidate hydrochloride extended-release capsules in the 25, 30, 35, and 40 mg strengths under § 505(j) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 355(j), shall not be earlier than the expiration dates of the '398 patent and '325 patent, including any extensions;
- C. A preliminary injunction, pursuant to 35 U.S.C. § 271(e)(4)(B) and 35 U.S.C. § 283, restraining and enjoining Teva from infringing the '398 and '325 patents by the commercial manufacture, use, offer to sell, or sale within the United States, or importation into the United States, of dexamethylphenidate hydrochloride extended-release capsules in the 30 and 40 mg strengths approved under ANDA No. 202731 pending a final judgment in this action;
- D. A permanent injunction, pursuant to 35 U.S.C. § 271(e)(4)(B), restraining and enjoining Teva, its officers, agents, servants, and employees, and those persons in active concert or participation with them, from infringement of the '398 and '325 patents for the full terms thereof, including any extensions;
- E. A declaration that this is an exceptional case and an award of reasonable attorneys' fees pursuant to 35 U.S.C. § 285;
- F. Costs and expenses in this action; and

G. Such other and further relief as the Court may deem just and proper.

MORRIS, NICHOLS, ARSHT & TUNNELL LLP



Jack B. Blumenfeld (#1014)
Maryellen Noreika (#3208)
Richard J. Bauer (#4828)
Jeremy A. Tigan (#5239)
1201 N. Market Street
P.O. Box 1347
Wilmington, DE 19899-1347
(302) 658-9200
jblumenfeld@mnat.com
mnoreika@mnat.com
rbauer@mnat.com
jtigan@mnat.com

*Attorneys for Plaintiff Alkermes
Pharma Ireland Limited*

December 1, 2011
4604017.1